Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can an antiviral make radiation more effective against cervical cancer?

NCT ID NCT02515877

Disease control Sponsor: Gustave Roussy, Cancer Campus, Grand Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 13, 2026 · Last updated Aug 14, 2026 · Updated 1 time

Summary

This phase 1 trial is testing whether adding the antiviral drug Vistide (cidofovir) to the standard combination of radiation and chemotherapy can improve outcomes for people with HPV-positive cervical cancer. The idea is that Vistide may make cancer cells more sensitive to radiation by interfering with the viral proteins that help the cancer grow. The study includes about 15 adults with advanced cervical cancer and will focus on finding the safest dose and understanding side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Vistide (cidofovir) combined with standard external radiotherapy, brachytherapy, and carboplatin chemotherapy
What this could lead to
If successful, this approach could enhance the effectiveness of standard radiochemotherapy for cervical cancer, potentially improving local control and survival rates.
What could go wrong
This is an early-phase trial with a small number of participants, so the benefits are uncertain. The antiviral may not enhance treatment as hoped, and there is a risk of increased side effects from the combination.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

15 people

The number who actually took part.

Start date

Jan 2008

Finished

Apr 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Patients with cervix cancer : Squamous cell carcinoma or adenocarcinoma of stage IB2\> 4 cm, II, III or IVA (International Federation of Gynecology Obstetrics, regardless of pelvic lymph node status (optional surgical exploration) without paraaortic metastasis. 2. Detection of the virus genome of HPV positive on the primary tumor. 3. General state ECOG performance status 0-1. 4. 18 \</ = age \</ = 70 years. 5. PN\> 2000 / mm3 6. hemoglobin\> 9 g/l after transfusion if necessary . 7. platelets \> 100 000 / mm3 8. Serum creatinine \<1.5 upper limit of normal. 9. Liver function tests (SGOT, SGPT, alkaline phosphatase and bilirubin) \<1.5 upper limit of normal. 10. Life expectancy\> 3 months. 11. Systematic Beta HCG Dosage for premenopausal women. 12. Informed consent signed after informing the patient. 13. Proteinuria \<2g / L (200mg / dL) and creatinine clearance of\> / = 55 ml / min. Exclusion Criteria: 1. Other histological types of cervix tumor than those mentioned in the inclusion criteria. 2. Search of viral sequences on the negative HPV tumor diagnosis. 3. History of cancer other than basal cell carcinoma. 4. Pre-treatment with radiotherapy or chemotherapy. 5. Ongoing pregnancy. 6. History or active psychiatric illness. 7. Nephropathy whatever the grade. 8. Infection scalable. 9. Active infection or other serious underlying pathology may prevent the patient receiving the treatment (in particular hepatic or cardiac). 10. Inclusion in another clinical trial protocol with an experimental molecule (during the study or within one month before inclusion). 11. Inability to submit to medical monitoring study for geographical, social or psychological.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cervical cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

cervical cancer Uterine Cervical Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cervical cancer

Contacts and locations

Locations

  • Gustave Roussy Cancer Campus Grand Paris

    Villejuif, Val de Marne, 94805, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.